The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

Lisette Bevaart; Marco J H Jansen; Martine J van Vugt; J Sjef Verbeek; Jan G J van de Winkel; Jeanette H W Leusen

doi:10.1158/0008-5472.CAN-05-2856

The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

Lisette Bevaart
, Marco J H Jansen
, Martine J van Vugt
, J Sjef Verbeek
, Jan G J van de Winkel
, Jeanette H W Leusen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.

Original language	English
Pages (from-to)	1261-4
Number of pages	4
Journal	Cancer Research
Volume	66
Issue number	3
DOIs	https://doi.org/10.1158/0008-5472.CAN-05-2856
Publication status	Published - 1 Feb 2006

Keywords

Animals
Antibodies, Monoclonal
Antibody Specificity
Immunization, Passive
Lipid A
Lung Neoplasms
Melanoma, Experimental
Mice
Mice, Inbred C57BL
Mice, Knockout
Receptors, IgG
Journal Article

Access to Document

10.1158/0008-5472.CAN-05-2856

Cite this

@article{e76c5e7081344f6883330c8e17bfc39a,

title = "The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma",

abstract = "We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.",

keywords = "Animals, Antibodies, Monoclonal, Antibody Specificity, Immunization, Passive, Lipid A, Lung Neoplasms, Melanoma, Experimental, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptors, IgG, Journal Article",

author = "Lisette Bevaart and Jansen, \{Marco J H\} and \{van Vugt\}, \{Martine J\} and Verbeek, \{J Sjef\} and \{van de Winkel\}, \{Jan G J\} and Leusen, \{Jeanette H W\}",

year = "2006",

month = feb,

day = "1",

doi = "10.1158/0008-5472.CAN-05-2856",

language = "English",

volume = "66",

pages = "1261--4",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

AU - Bevaart, Lisette

AU - Jansen, Marco J H

AU - van Vugt, Martine J

AU - Verbeek, J Sjef

AU - van de Winkel, Jan G J

AU - Leusen, Jeanette H W

PY - 2006/2/1

Y1 - 2006/2/1

N2 - We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.

AB - We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.

KW - Animals

KW - Antibodies, Monoclonal

KW - Antibody Specificity

KW - Immunization, Passive

KW - Lipid A

KW - Lung Neoplasms

KW - Melanoma, Experimental

KW - Mice

KW - Mice, Inbred C57BL

KW - Mice, Knockout

KW - Receptors, IgG

KW - Journal Article

U2 - 10.1158/0008-5472.CAN-05-2856

DO - 10.1158/0008-5472.CAN-05-2856

M3 - Article

C2 - 16452176

SN - 0008-5472

VL - 66

SP - 1261

EP - 1264

JO - Cancer Research

JF - Cancer Research

IS - 3

ER -

The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this